CA3045243A1 - Polytherapie - Google Patents
Polytherapie Download PDFInfo
- Publication number
- CA3045243A1 CA3045243A1 CA3045243A CA3045243A CA3045243A1 CA 3045243 A1 CA3045243 A1 CA 3045243A1 CA 3045243 A CA3045243 A CA 3045243A CA 3045243 A CA3045243 A CA 3045243A CA 3045243 A1 CA3045243 A1 CA 3045243A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- antibody
- optionally substituted
- set forth
- immuno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne l'association d'un inhibiteur de la protéine arginine N-méthyltransférase de type II (PRMT de type II) et d'un agent immunomodulateur, l'agent immunomodulateur étant un anticorps anti-OX40 ou un fragment de liaison à l'antigène de ce dernier. La présente invention concerne également des méthodes de traitement du cancer chez le patient humain dont l'état nécessite de tels traitements, les méthodes comprenant l'administration au patient d'une association d'un inhibiteur de la PRM de type II et d'un agent immunomodulateur, l'agent immunomodulateur étant un anticorps anti-OX40 ou un fragment de liaison à l'antigène de ce dernier, avec au moins l'un des constituants suivants : un support pharmaceutiquement acceptable et un diluant pharmaceutiquement acceptable, l'invention permettant de cette façon de traiter le cancer chez l'humain. La présente invention concerne en outre une composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un inhibiteur de de la PRM de type II et une seconde composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un agent immunomodulateur, l'agent immunomodulateur étant un anticorps anti-OX40 ou un fragment de liaison à l'antigène de ce dernier.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662428764P | 2016-12-01 | 2016-12-01 | |
US62/428,764 | 2016-12-01 | ||
US201662433363P | 2016-12-13 | 2016-12-13 | |
US62/433,363 | 2016-12-13 | ||
PCT/IB2017/057549 WO2018100535A1 (fr) | 2016-12-01 | 2017-11-30 | Polythérapie |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3045243A1 true CA3045243A1 (fr) | 2018-06-07 |
Family
ID=60782286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3045243A Abandoned CA3045243A1 (fr) | 2016-12-01 | 2017-11-30 | Polytherapie |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3548068A1 (fr) |
JP (1) | JP2020511407A (fr) |
KR (1) | KR20190090823A (fr) |
CN (1) | CN110234342A (fr) |
AU (1) | AU2017369994A1 (fr) |
BR (1) | BR112019011350A2 (fr) |
CA (1) | CA3045243A1 (fr) |
WO (1) | WO2018100535A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型***类化合物的合成及应用 |
US20230301998A1 (en) * | 2020-05-04 | 2023-09-28 | Sanford Burnham Prebys Medical Discovery Institute | Methods and compositions for induction of antitumor immunity |
CN113908283A (zh) * | 2021-09-30 | 2022-01-11 | 上海交通大学医学院附属新华医院 | Prmt5抑制剂及其与pd-l1抗体阻断剂联合在治疗肺癌上的应用 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
AP1590A (en) | 1998-12-23 | 2006-03-14 | Pfizer | Human monoclonal antibodies to CTLA-4. |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1261376A1 (fr) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Anticorps contre ctla4 (cd152), conjugues comprenant lesdits anticorps, et leurs utilisations |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
WO2003042402A2 (fr) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents modulant l'activite de cellules immunes et procedes d'utilisation associes |
CN100360565C (zh) | 2001-12-22 | 2008-01-09 | 4-抗体股份公司 | 制备脊椎动物淋巴细胞和生产结合蛋白的方法 |
IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
US7550140B2 (en) | 2002-06-13 | 2009-06-23 | Crucell Holland B.V. | Antibody to the human OX40 receptor |
EP3287144A1 (fr) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Compositions immunostimulantes |
CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
EP1591527B1 (fr) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specifique a pd-1 humain |
AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
US20090311280A1 (en) | 2004-12-09 | 2009-12-17 | La Jolla Institute For Allergy And Immunology | Novel tnf receptor regulatory domain |
EP2418278A3 (fr) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
US20080286286A1 (en) | 2006-01-13 | 2008-11-20 | Board Of Regents, The University Of Texas System | Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor |
GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
EP3222634A1 (fr) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Anticorps dirigés contre le récepteur humain de mort programmée pd-1 |
KR101577843B1 (ko) | 2007-12-14 | 2015-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 ox40 수용체에 대한 결합 분자 |
US8168757B2 (en) * | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドIsis Innovationlimited | Pd−1特異抗体およびその使用 |
JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Pd−1特異抗体およびその使用 |
CN108484767B (zh) | 2008-09-26 | 2022-01-14 | 达纳-法伯癌症研究公司 | 人抗pd-1、pd-l1和pd-l2的抗体及其应用 |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
KR101934071B1 (ko) | 2009-11-24 | 2019-01-02 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
US9044432B2 (en) | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
WO2013028231A1 (fr) | 2011-08-23 | 2013-02-28 | Board Of Regents, The University Of Texas System | Anticorps anti-ox40 et leurs procédés d'utilisation |
EP2609118B1 (fr) | 2010-08-23 | 2017-01-18 | Board Of Regents, The University Of Texas System | Anticorps anti-ox40 et leurs procédés d'utilisation |
ES2708669T3 (es) | 2011-08-01 | 2019-04-10 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de MEK |
AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
US9212224B2 (en) * | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
CA2894126A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
KR102173874B1 (ko) * | 2012-12-21 | 2020-11-05 | 에피자임, 인코포레이티드 | 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도 |
EP3406607A1 (fr) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Inhibiteurs prmt5 contenant de la dihydro- ou tétrahydroisoquinoline et leurs utilisations |
WO2014100716A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
US20150344457A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | Methods of inhibiting prmt5 |
EP2935247B1 (fr) | 2012-12-21 | 2019-08-28 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
US20180271891A1 (en) * | 2015-03-11 | 2018-09-27 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
-
2017
- 2017-11-30 JP JP2019529614A patent/JP2020511407A/ja not_active Withdrawn
- 2017-11-30 CA CA3045243A patent/CA3045243A1/fr not_active Abandoned
- 2017-11-30 CN CN201780084564.XA patent/CN110234342A/zh active Pending
- 2017-11-30 AU AU2017369994A patent/AU2017369994A1/en not_active Abandoned
- 2017-11-30 WO PCT/IB2017/057549 patent/WO2018100535A1/fr unknown
- 2017-11-30 KR KR1020197018433A patent/KR20190090823A/ko unknown
- 2017-11-30 EP EP17818288.7A patent/EP3548068A1/fr not_active Withdrawn
- 2017-11-30 BR BR112019011350A patent/BR112019011350A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR112019011350A2 (pt) | 2019-10-22 |
JP2020511407A (ja) | 2020-04-16 |
KR20190090823A (ko) | 2019-08-02 |
CN110234342A (zh) | 2019-09-13 |
EP3548068A1 (fr) | 2019-10-09 |
AU2017369994A1 (en) | 2019-06-13 |
WO2018100535A1 (fr) | 2018-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016331190A1 (en) | Combination therapy of bromodomain inhibitors and checkpoint blockade | |
CA3045243A1 (fr) | Polytherapie | |
US20230094076A1 (en) | Combination therapy | |
JP2018516884A (ja) | コルチスタチン誘導体による治療に対する患者の標的化選択 | |
JP2023075286A (ja) | 癌を治療するためのii型タンパク質アルギニンメチルトランスフェラーゼ阻害剤及びicos結合タンパク質の組合せ | |
JP2023052400A (ja) | 併用療法 | |
EP3394038A1 (fr) | Sélection ciblée de patients en vue d'un traitement avec des dérivés de cortistatine spécifiques | |
US20190350931A1 (en) | Combination therapy | |
US20210260033A1 (en) | Combined therapy with icos binding proteins and argininemethyltransferase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20230530 |